Phase II Study to Test Pembrolizumab (MK-3475) in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 Low Expressors).
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms PEOPLE
- 31 Aug 2018 Biomarkers information updated
- 04 Jun 2018 Planned End Date changed from 1 Mar 2021 to 1 May 2021.
- 04 Jun 2018 Planned primary completion date changed from 1 Mar 2021 to 1 May 2021.